Hkstp partner firm becomes city’s first recognised stem cell production facility Hong Kong Standard 5d
CSD and HKSTP renew MOU to deepen sustainable development of Smart Prison (with photos) The Government of Hong Kong Special Administrative Region (Press Release) 7d
Hkstp signs MoU with IT Park Uzbekistan to deepen cross-regional innovation collaboration Hong Kong Standard 18:43 Wed, 15 Jul
Jarrow star donates stem cells to aid kid's battle with leukaemia Shields Gazette 14h Biology Article paywall
Indefinite-duration maintenance Therapy no better than fixed-duration Therapy in multiple myeloma Oncology Nurse Advisor 4d
Decoy therapeutics expands Intellectual Property portfolio covering Designable Multi-Antivirals and the imp³act™ platform PR Newswire (Press Release) 6h Biotechnology
Rocket pharmaceuticals announces positive clinical safety update from initial three patients treated with RP-A501 under modified Phase 2 protocol for danon disease Business Wire (Press Release) 7h Biotechnology
Amgen says cloud data breach exposed patient health, proprietary info BleepingComputer.com 3d Amgen Pharma Technology
The startup behind the pill for Sleep Apnea raises $192 million in IPO Forbes 4d Apnimed Biotech Pharma All sources
SK biopharmaceuticals, Eurofarma expand cenobamate partnership during President Lee’s Brazil visit Korea Biomedical Review 6d Biotech Pharma All sources
Biotech giant Amgen says patient data stolen from third-party cloud systems The Record 5h Amgen Biotech Pharma All sources
Johnson & Johnson shares edge higher as $3.5B Biotech moves expand oncology pipeline Benzinga 3d Johnson and Johnson Pharma Article paywall All sources
AstraZeneca and Bristol-Myers Squibb: Megamerger reports leave us scratching our heads MorningStar.com 3h Bristol Myers Squibb AstraZeneca
FTSE 100 movers: AstraZeneca tumbles on merger report; housebuilders rally ShareCast 4h AstraZeneca Article paywall
Drug giants AstraZeneca, BMS weighing $400 bn tie-up: report Macau Business 5h Bristol Myers Squibb AstraZeneca
Jim cramer senses a 'Fake out' in rumored AstraZeneca, Bristol Myers Squibb $400 billion mega-merger Benzinga 6h Bristol Myers Squibb AstraZeneca Article paywall
